GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Degree of Financial Leverage

Baudax Bio (Baudax Bio) Degree of Financial Leverage : -4.14 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Baudax Bio's Degree of Financial Leverage for the quarter that ended in Sep. 2023 was -4.14. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Baudax Bio's Degree of Financial Leverage or its related term are showing as below:

BXRXQ's Degree of Financial Leverage is ranked better than
96.33% of 1499 companies
in the Biotechnology industry
Industry Median: 0.96 vs BXRXQ: -4.14

Baudax Bio Degree of Financial Leverage Historical Data

The historical data trend for Baudax Bio's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Degree of Financial Leverage Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial - -1.20 0.42 3.10 1.53

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.53 1.77 -11.78 -4.14

Competitive Comparison of Baudax Bio's Degree of Financial Leverage

For the Biotechnology subindustry, Baudax Bio's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Degree of Financial Leverage falls into.



Baudax Bio Degree of Financial Leverage Calculation

Baudax Bio's Degree of Financial Leverage for the quarter that ended in Sep. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -9.23 (Sep. 2023) / 133.68 (Sep. 2022) - 1 )/( -35.023 (Sep. 2023) / -27.842 (Sep. 2022) - 1 )
=-1.069/0.2579
=-4.14***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Baudax Bio  (OTCPK:BXRXQ) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Baudax Bio Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341